Antioxidant strategies in protection against neurodegenerative disorders

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 10, 2003, Pages 1513-1543

  Tan, Dun Xian ^a   Manchester, Lucien C ^b   Sainz, Rosa ^a   Mayo, Juan C ^a   Alvares, Frederick L ^b   Reiter, Russel J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b ST MARY'S UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Antioxidant; Free radical; Neurodegenerative disease; Oxidative stress; Parkinson's disease; Reactive nitrogen species (RNS); Reactive oxygen species (ROS); Stroke

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOPHEROL DERIVATIVE; AMYLOID BETA PROTEIN; ANTIOXIDANT; ASCORBIC ACID; CURCUMIN; DEFEROXAMINE; DEFEROXAMINE MESYLATE; DISUFENTON SODIUM; EBSELEN; FREE RADICAL; GINKGO BILOBA EXTRACT; GLUTATHIONE; GLUTATHIONE ISOPROPYL ESTER; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HYDROGEN PEROXIDE; HYPOCHLOROUS ACID; LEVODOPA; LIPOXYGENASE; MELATONIN; METAL CHELATE; NITRIC OXIDE SYNTHASE; OXYGEN RADICAL; PEROXYNITRITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SELEGILINE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD BRAIN BARRIER; CELLULAR DISTRIBUTION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG FORMULATION; DRUG METABOLISM; GINKGO BILOBA; HUMAN; MITOCHONDRION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATENT; REVIEW; TREATMENT OUTCOME;

EID: 0242573381     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.10.1513     Document Type: Review

References (306)

1. GILBERT DL: Fifty years of radical ideas. Ann. NY Acad. Sci. (2000) 899:1-14.
2. FANG YZ, YANG S, WU G: Free radicals, antioxidants, and nutrition. Nutrition (2002) 18:872-879.
3. SYMONS MCR, GUTTERIDGE JMC: Free Radical and Iron. In: Chemistry, Biology, and Medicine. Oxford Unversity Press, UK (1998):6-12.
4. KANG D, NARABAYASHI H, SATA T, TAKESHIGE K: Kinetics of superoxide formation by respiratory chain NADH-dehydrogenase of bovine heart mitochondria. J. Biochem. (1983) 94:1301-1306.
5. EVANS P, HALLIWELL B: Micronutrients: oxidant/antioxidant status. Br. J. Nutr. (2001) 85(Suppl.2):S67-S74.
6. COYLE JT, PUTTFARCHEN P: Oxidative stress, glutamate and neurodegenerative disorders. Science (1993) 262:689-695.
7. MARLETTA MA: Nitric oxide synthase structure and mechanism. J. Biol. Chem. (1993) 268:12231-12234.
8. HARE JM: Nitric oxide and excitation-contraction coupling. J. Mol. Cell. Cardiol. (2003) 35:719-29.
9. HALLIWELL B, GUTTERIDGE JMC: Oxygen toxicity, oxygen free radicals, transition metals and disease. Biochem. J. (1984) 219:1-4.
10. LANDER HM: An essential role for free radicals and derived species in signal transduction. FASEB J. (1997) 11:118-124.
11. PRAST H, PHILIPPU A: Nitric oxide as modulator of neuronal function. Prog. Neurobiol. (2001) 64:51-68.
12. KELM M: The L-arginine-nitric oxide pathway in hypertension. Curr. Hypertens Rep. (2003) 5:80-86.
13. BOGDAN C: Nitric oxide and the immune response. Nat. Immunol. (2001) 2:907-916.
14. KELM M: Fundamental aspects of reactive oxygen species, or what's the matter with oxygen? Ann. NY Acad. Sci. (1999) 893:13-18.
15. AMES BN: Endogenous DNA damage as related to cancer and aging. Mutat. Res. (1989) 214:41-46.
16. STADTMAN ER: Protein oxidation in aging and age-related diseases. Ann. NY Acad. Sci. (2001) 928:22-38.
17. KHAN FH, SAHA M, CHAKRABARTI S: Dopamine-induced protein damage in mitochondrial-synaptosomal fraction of rat brain. Brain. Res. (2001) 895:245-249.
18. GUTTERIDGE JM, HALLIWELL B: Reoxygenation injury and antioxidant protection: a tale of two paradoxes. Arch. Biochem. Biophys. (1990) 283:223-226.
19. ESTERBAUER H, ECKL P, ORTNER A: Possible mutagens derived from lipids and lipid precursors. Mutat. Res. (1990) 238:223-233.
20. BRIVIBA K, SIES H: Non-enzymatic antioxidative defense systems. In: Natural Antioxidants in Human Health and Disease.. Frei B (Ed.) Academic Press, San Diego, USA (1994):107-128.
21. AHMAD S: Antioxidant mechanisms of enzymes and proteins. In Oxidative Stress and Antioxidative Defenses in Biology Ahmad S (Ed.) Chapman and Hall. New York, USA (1995):238-272.
22. MAISTER A: On the antioxidant effect of ascorbic acid and glutathione. Biochem. Pharmacol. (1992) 44:1905-1915.
23. MOOSMANN B, BEHL C: Antioxidants as treatment for neurodegenerative disorders, Expert Opin. Investing. Drugs (2002) 11:1407-1435.
24. LIU B, GAO HM, WANG JY, JEOHN GH, COOPER CL, HONG JS: Role of nitric oxide in inflammation-mediated neurodegeneration. Ann. NY Acad. Sci. (2002) 962:318-331.
25. CALINGASAN NY, GIBSON GE: Vascular endothelium is a site of free radical production and inflammation in areas of neuronal loss in thiamine-deficient brain. Ann. NY Acad. Sci. (2000) 903:353-356.
26. MCGEER EG, MCGEER PL: Inflammatory processes in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry (2003) 27:741-749.
27. BEAL MF: Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. NY Acad. Sci. (2003) 991:120-131.
28. BAZAN NG, COLANGELO V, LUKIW WJ: Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediat. (2002) 68:197-210.
29. VAN DER VEEN RC, HINTON DR, INCARDONNA F, HOFMAN FM: Extensive peroxynitrite activity during progressive stages of central nervous system inflammation. J. Neuroimmunol. (1997) 77:1-7.
30. LIU Y, ZHU B, WANG X et al.: Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. J. Neuroimmunol. (2003) 139:27-35.
31. MOHAMED A, SHOKER A, BENDJELLOUL F et al: Improvement of experimental allergic encephalomyelitis (EAE) by thymoquinone; an oxidative stress inhibitor. Biomed. Sci. Instrum. (2003) 39:440-445.
32. MARTINEY JA, RAJAN AJ, CHARLES PC et al.: Prevention and treatment of experimental autoimmune encephalomyelitis by CNI-1493, a macrophage-deactivating agent. J. Immunol. (1998) 160:5588-5595.
33. ROBBERECHT W, SAPP P, VIAENE MU et al.: Cu/Zn superoxide dismutase activity in familial and soporadic amytrophic lateral scelerosis. J. Neurochem. (1994) 62:1384-1387.
34. LUETJENS CM, BUI NT SENGPIEL B et al.: Delayed mitochondrial dysfunction in excitotoxic neuron death: cytochrome c release and a secondary increase in superoxide production. J. Neurosci. (2000) 20:5715-5723.
35. CALINGASAN NY, CHUN WJ, PARK LC, UCHIDA K, GIBSON GE: Oxidative stress is associated with region-specific neuronal death during thiamine deficiency. J. Neuropathol. Exp. Neurol. (1999) 58:946-958.
36. EVANS PH, YANO E, KLINOWSKI J, PETERHANS E: Oxidative damage in Alzheimer's dementia, and the potential etiopathogenic role of aluminosilicates, microglia and micronutrient interactions. EXS (1992) 62:178-189.
37. HALLIWELL B, CLEMENT MV, LONG LH: Hydrogen peroxide in the human body. FEBS Lett. (2000) 486:10-13.
38. NUNOMURA A, PERRY G, ALIEV G et al.: Oxidative damage is the earliest event in Alzheimer's disease. J. Neuropathol. Exp. Neurol. (2001) 60:759-767.
39. SWERDLOW RH, PARKS JK, PATTEE G, PARKER WD Jr: Role of mitochondria in amyotrophic lateral sclerosis. Neuron Disord. (2000) 1:185-190.
40. DIKRANIAN K, ISHIMARU MJ, TENKOVA T et al.: Apoptosis in the in vivo mammalian forebrain. Neurobiol. Dis. (2001) 8:359-379.
41. EBADI M, SRINIVASAN SK, BAXI MD: Oxidative stress and antioxidant therapy in Parkinson's disease. Prog. Neurobiol. (1996) 48:1-19.
42. PITCHUMONI SS, DORAISWAMY PM: Current status of antioxidant therapy for Alzheimer's disease. J. Am. Geriatr. (1998) 46:1566-1572.
43. OKEN BS, STORZBACH DM, KAYE JA: The efficacy of Ginkgo biloba on cognitive function in Alzheimer's disease. Arch. Neurol. (1998) 55:1409-1415.
44. BARNEOUD P, CURET O: Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on moter performance in a transgenic model of amyotrophic lateral sclerosis. Exp. Neurol. (1999) 155:234-251.
45. GREENWOOD J: The blood-retinal barrier in experimental autoimmune uveoretinitis (EAU): a review. Curr. Eye Res. (1992) 11(Suppl.):25-32.
46. GILGUN-SHERKI Y, MELAMED E, OFFEN D: Oxidative stress-induced neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology (2001) 40:959-975.
47. WEISER H, VECCHI M: Stereoisomers of α-tocopheryl acetate. II. Biopotencies of all eight stereoisomers, individually or in mixtures, as determined by the rat resorption/gestation test. Int. J. Vitam. Nutr. Res. (1982) 52:351-370.
48. MARTIN A, CHERUBINI A, ANDRES-LACUEVA C, PANIAGUA M, JOSEPH J: Effects of fruits and vegetables on levels of vitamins E and C in the brain and their association with cognitive performance. J. Nutr. Health Aging. (2002) 6:392-404.
49. BLATT DH, LEONARD SW, TRABER MG: Vitamin E kinetics and the function of tocopherol regulatory proteins. Nutrition (2001) 17:799-805.
50. GOTI D, HAMMER A, GALLA HJ, MALLE E, SATTLER W: Uptake of lipoprotein-associated α-tocopherol by primary porcine brain capillary endothelial cells. J. Neurochem. (2000) 74:1374-1383.
51. WALLSTROM P, WIRFALT E, LAHMANN PH, GULLBERG B, JANZON L, BERGLUND G: Serum concentrations of β-carotene and α-tocopherol are associated with diet, smoking, and general and central adiposity. Am. J. Clin. Nutr. (2001) 73:777-785.
52. VATASSERY GT, FAHN S, KUSKOWSKI MA: α-Tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group. Neurology (1998) 50:1900-1902.
53. LEONARD SW, TERASAWA Y, FARESE RV JR, TRABER MG: Incorporation of deuterated RRR- or all-rac-α-tocopherol in plasma and tissues of α-tocopherol transfer protein-null mice. Am. J. Clin. Nutr. (2002) 75:555-560.
54. COPP RP, WISNIEWSKI T, HENTATI F, LARNAOUT A, BEN HAMIDA M, KAYDEN HJ: Localization of α-tocopherol transfer protein in the brains of patients with ataxia with vitamin E deficiency and other oxidative stress-related neurodegenerative disorders. Brain Res. (1999) 822:80-87.
55. KOLL M, BEESO JA, KELLY FJ et al.: Chronic α-tocopherol supplementation in rats does not ameliorate either chronic or acute alcohol-induced changes in muscle protein metabolism. Clin. Sci. (2003) 104:287-294.
56. SACHECK JM, MILBURY PE, CANNON JG, ROUBENOFF R, BLUMBERG JB: Effect of vitamin E and eccentric exercise on selected biomarkers of oxidative stress in young and elderly men. Free Radic. Biol. Med. (2003) 34:1575-1588.
57. 14C tracer and product studies. Biochim. Biophys. Acta. (1995) 1237:77-85.
58. GUO Q, PACKER L: Ascorbate-dependent recycling of the vitamin E homologue Trolox by dihydrolipoate and glutathione in murine skin homogenates. Free Radic. Biol. Med. (2000) 29:368-374.
59. MULLER DPR: Vitamin E and neurological function: lessons from patients with abetalipoproteinaemia. Redox Rep. (1995) 1:239-245.
60. DE KUMAR A, RUKMINI D: Physiological antioxidants and antioxidant enzymes in vitamin E-deficient rats. Toxicol. Lett. (1988) 44:47-54.
61. CRANDON JH, LUND CC, DILL DB: Experimental human scurvy. N. Engl. J. Med. (1940) 223:353-369.
62. ENGLARD S, SOFTER S: The biochemical functions of ascorbic acid. Ann. Rev. Nutr. (1986) 6:365-406.
63. CHANVITAYAPONGS S, DRACZYNSKA-LUSIAK B, SUN AY: Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. Neuroreport (1997) 8:1499-1502.
64. RAMANATHAN K, BALAKUMAR BS, PANNEERSELVAM C: Effects of ascorbic acid and α-tocopherol on arsenic-induced oxidative stress. Hum. Exp. Toxicol. (2002) 21:675-680.
65. DE MARTINIS BS, BIANCHI MD: Effect of vitamin C supplementation against cisplatin-induced toxicity and oxidative DNA damage in rats. Pharmacol. Res. (2001) 44:317-320.
66. CHAN AC: Partners in defense. Vitamin E and vitamin C. Can. J. Physiol. Pharmacol. (1993) 7:725-731.
67. HORNIG D: Distribution of ascorbic acid, metabolites and analogues in man and animals. Ann. NY Acad. Sci. (1975) 258:103-118.
68. ARGUS DB, GAMBHIR SS, PARDRIDGE WM et al.: Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J. Clin. Invest. (1997) 100:2842-2848.
69. DENEKE SM: Thiol-based antioxidants. Curr. Top. Cell. Regul. (2000) 36:151-180.
70. PEARCE RK, OWEN A, DANIEL S, JENNER P, MARSDEN CD: Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural. Transm. (1997) 104:661-677.
71. SCHULZ JB, LINDENAU J, SEYFRIED J, DICHGANS J: Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. (2000) 267:4904-4911.
72. YAMAMOTO M, SAKAMOTO N, IWAI A et al.: Protective actions of YM-737, a new glutathione analog, against cerebral ischemia in rats. Res. Commun. Chem. Pathol. Pharmacol. (1993) 81:221-232.
73. GIESS R, HOLTMANN B, BRAGA M et al.: Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene. Am. J. Hum. Genet. (2002) 70:1277-1286.
74. KISH SJ, MORITO C, HORNYKIEWICZ O: Glutathione peroxidase activity in Parkinson's disease brain. Neurosci. Lett. (1985) 58:343-346.
75. SAGARA Y, DARGUSCH R, KLIER FG: Increased antioxidant enzyme activity in amyloid β protein-resistant cells. J. Neurosci. (1996) 16:497-505.
76. NAKAO N, FRODL EM, WIDNER H et al.: Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nat. Med. (1995) 1:226-231.
77. MUGESH G, DU MONT WW: Structure-activity correlation between natural glutathione peroxidase (GPx) and mimics: a biomimetic concept for the design and synthesis of more efficient GPx mimics. Chemistry (2001) 7:1365-1370.
78. IMAI H, GRAHAM DI, MASAYASU H, MACRAE IM: Antioxidant ebselen reduces oxidative damage in focal cerebral ischemia. Free Radic. Biol. Med: (2003) 34:56-63.
79. BURGER ME, ALVES A, CALLEGARI L et al.: Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum. Prog. Neuropsychopharmacol. Biol. Psychiatry (2003) 27:135-140.
80. CASTAGNE V, CLARKE PG: Neuroprotective effects of a new glutathione peroxidase mimetic on neurons of the chick embryo's retina. J. Neurosci. Res. (2000) 59:497-503.
81. PONG K: Oxidative stress in neurodegenerative disease: therapeutic implications for superoxide dismutase mimetics. Expert. Opin. Biol. Ther. (2003) 3:127-139.
82. MOLLACE V, IANNONE M, MUSCOLI C et al.: The protective effect of M-40401, a superoxide dismutase mimetic, on post-ischemic brain damage in Mongolian gerbils. BMC Pharmacol. (2003) Jun 16 [Electronically published ahead of print].
83. WU DC, JACKSON-LEWIS V, VILA M et al.: Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci. (2002) 22:1763-1771.
84. DOCTROW SR, HUFFMAN K, MARCUS CB et al.: Salen-manganese complexes: combined superoxide dismutase/catalase mimics with broad pharmacological efficacy. Adv. Pharmacol. (1997) 38:247-269.
85. JUNG C, RONG Y, DOCTROW S, BAUDRY M, MALFROY B, XU Z: Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model. Neurosci. Lett. (2001) 304:157-160.
86. HARDELAND R, BALZER I, POEGGELER B et al.: On the primary functions of melatonin in evolution: mediation of photoperiodic signals in a unicell, photooxidation, and scavenging of free radicals. J. Pineal Res. (1995) 18:104-111.
87. REITER RJ: Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocrine Rev. (1991) 12:151-180.
88. MANCHESTER LC, TAN DX, REITER RJ, PARK W, MONIS K, QI W: High levels of melatonin in the seeds of edible plants: possible function in germ tissue protection. Life Sci. (2000) 67:3023-3029.
89. TAN DX, MANCHESTER LC, HARDELAND R: Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J. Pineal. Res. (2003) 34:75-78.
90. CHEN G, HUO Y, TAN DX, LIANG Z, ZHANG W, ZHANG Y: Melatonin in Chinese medicinal herbs. Life Sci. (2003) 73:19-26.
91. TRICOIRE H, LOCATELLI A, CHEMINEAU P, MALPAUX B: Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology (2002) 143:84-90.
92. TAN DX, CHEN LD, POEGGELER B, MANCHESTER LC, REITER RJ: Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine J. (1993) 1:57-60.
93. REITER RJ: Oxidative damage in the central nervous system: protection by melatonin. Prog. Neurobiol. (1998) 56:359-384.
94. REITER RJ, GUERRERO JM, GARCIA JJ, ACUNA-CASTROVIEJO D: Reactive oxygen intermediates, molecular damage and aging: relation to melatonin. Ann. NY Acad. Sci. (1998) 854:410-454.
95. BARLOW-WALDEN L, REITER RJ, ABE M et al.: Melatonin stimulates brain glutathione peroxidase activity. Neurochem. Int. (1995) 26:947-502.
96. URATA Y, HONMA S, GOTO S et al.: Melatonin induces γ-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic. Biol. Med (1999) 27:838-847.
97. TAN DX, REITER RJ, MANCHESTER LC et al.: Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr. Top. Med. Chem. (2002) 2:181-197.
98. HUSSON I, MESPLES B, BAC P, VAMECQ J, EVRARD P, GRESSENS P: Melatoninergic neuroprotection of the murine periventricular white matter against neonatal excitotoxic challenge. Ann. Neurol. (2002) 51:82-92.
99. SHIDA CS, CASTRUCCI AML, LAMY-FREUND MT: High melatonin solubility in aqueous medium. J. Pineal Res. (1994) 16:198-201.
100. COSTA EJX, SHIDA CS, BIAGGI MH, ITO AS, LAMY-FREUND MT: How melatonin interacts with lipid bilayes: a study by fluorescence and ESR spectroscopies. FEBS Lett. (1997) 416:103-106.
101. CERAULO L, FERRUGIA M, TESORIERE L, SEGRETO S, LIVREA MA, LIVERT VT: Interactions of melatonin with membrane models: portioning of melatonin in AOT and lecithin reversed micelles. J. Pineal Res. (1999) 26:108-112.
102. MARTIN M, MACIAS M, ESCAMES G, LEON J, ACUNA-CASTROVIEJO D: Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress. FASEB. J. (2000) 14:2128-2130.
103. MENENDEZ-PELAEZ A, POEGGELER B, REITER RJ, BARLOW-WALDEN L, PABLOS MI, TAN DX: Nuclear localization of melatonin in different mammalian tissues: immunocytochemical and radioimmunoassay evidence. J. Cell. Biochem. (1993) 53:373-382.
104. CHYAN YJ, POEGGELER B, OMAR RA et al.: Potent neuroprotective properties against the Alzheimer β-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J. Biol. Chem. (1999) 274:21973-21942.
105. CHAN TY, TANG PL: Characterization of antioxidant effects of melatonin and related indoleamines in vitro. J. Pineal Res. (1996) 20:187-191.
106. NAPPI AJ, VASS E: Comparative studies of enhanced iron-mediated production of hydroxyl radical by glutathione, cysteine, ascorbic acid, and selected catechols. Biochem. Biophys. Acta (1997) 1336:295-302.
107. FEIGIN VL, LAWES CM, BENNETT DA, ANDERSON CS: Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. (2003) 2:43-53.
108. BERGEN DC, SILBERBERG D: Nervous system disorders: a global epidemic. Arch. Neurol. (2002) 59:1194-1196.
109. WHO: The World Health Report 2000, Geneva: WHO (2000).
110. WHITE BC, SULLIVAN JM, DEGRACIA DJ et al.: Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J. Neurol. Sci. (2000) 179(S1-2):1-33.
111. HUANG Z, HUANG PL, PANAHIAN N, DALKARA T, FISHMAN MC, MOSKOWITZ MA. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science. (1994) 265:1883-1885.
112. KINOUCHI H, EPSTEIN CJ, MIZUE T, CARLSON E, CHEN SF, CHAN PH: Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase. Proc. Natl. Acad. Sci. USA (1991) 88:11158-11162.
113. TAGAMI M, IKEDA K, YAMAGATA K et al.: Vitamin E prevents apoptosis in hippocampal neurons caused by cerebral ischemia and reperfusion in stroke-prone spontaneously hypertensive rats. Lab. Invest. (1999) 79:609-615.
114. VAN DER WORP HB, THOMAS CE, KAPPELLE LJ, HOFFMAN WP, DE WILDT DJ, BAR PR: Inhibition of iron-dependent and ischemia-induced brain damage by the α-tocopherol analogue MDL-74,722. Exp. Neurol. (1999) 155:103-108.
115. DAGA MK, MADHUCHHANDA, MISHRA TK, MOHAN A: Lipid peroxide, β-carotene and α-tocopherol in ischaemic stroke and effect of exogenous vitamin E supplementation on outcome. J. Assoc. Physicians India. (1997) 45:843-846.
116. YOCHUM LA, FOLSOM AR, KUSHI LH: Intake of antioxidant vitamins and risk of death from stroke in postmenopausal women. Am. J. Clin. Nutr. (2000) 72:476-483.
117. SCIAMANNA MA, LEE CP: Ischemia/reperfusion-induced injury of forebrain mitochondria and protection by ascorbate. Arch. Biochem. Biophys. (1993) 305:215-24.
118. RANJAN A, THEODORE D, HARAN RP, CHANDY MJ: Ascorbic acid and focal cerebral ischaemia in a primate model. Acta Neurochir. (1993) 123:87-91.
119. HENRY PT, CHANDY MJ: Effect of ascorbic acid on infarct size in experimental focal cerebral ischaemia and reperfusion in a primate model. Acta Neurochir. (1998) 140:977-980.
120. CHERUBINI A, POLIDORI MC, BREGNOCCHI M et al.: Antioxidant profile and early outcome in stroke patients. Stroke (2000) 31:2295-2300.
121. POLIDORI MC, FREI B, CHERUBINI A et al.: Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke. Free Radic. Biol. Med. (1998) 25:561-567.
122. POLIDORI MC, MECOCCI P, FREI B: Plasma vitamin C levels are decreased and correlated grain damage in patients with intracranial hemorrhage head trauma. Stroke (2001) 32:898-902.
123. WOLF PA: Epidemiology and risk factor management. In: Primer on Cerebrovascular Disease (Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B (Eds) Academic Press, San Diego, USA (1997):751-757.
124. PARK EM, CHOI JH, PARK JS, HAN MY, PARK YM: Measurement of glutathione oxidation and 8-hydroxy-2′-deoxyguanosine accumulation in the gerbil hippocampus following global ischemia. Brain. Res. Protoc. (2000) 6:25-32.
125. MARTINEZ G, CARNAZZA ML, CAMPISI A et al.: Effects of glutathione depletors on post-ischemic reperfusion in rat brain. Neurochem. Res. (1998) 23:961-968.
126. SEKHON B, SEKHON C, KHAN M, PATEL SJ, SINGH I, SINGH AK: N-acetyl cysteine protects against injury in a rat model of focal cerebral ischemia. Brain Res. (2003) 971:1-8.
127. JOHSHITA H, SASAKI T, MATSUI T et al.: Effects of ebselen (PZ51) on ischaemic brain oedema after focal ischaemia in cats. Acta. Neurochir. Suppl. (1990) 51:239-241.
128. DAWSON DA, MASAYASU H, GRAHAM DI, MACRAE IM: The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat. Neurosci. Lett. (1995) 185:65-69.
129. TAKASAGO T, PETERS EE, GRAHAM DI, MASAYASU H, MACRAE IM: Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Br. J. Pharmacol. (1997) 122:1251-1256.
130. NAMURA S, NAGATA I, TAKAMI S, MASAYASU H, KIKUCHI H: Ebselen reduces cytochrome c release from mitochondria and subsequent DNA fragmentation after transient focal cerebral ischemia in mice. Stroke (2001) 32:1906-1911.
131. YAMAGUCHI T, SANO K, TAKAKURA K et al.: Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke (1998) 29:12-17.
132. BAKER K, MARCUS CB, HUFFMAN K, KRUK H, MALFROY B, DOCTROW SR: Synthetic combined superoxide dismutase/catalase mimetics are protective as a delayed treatment in a rat stroke model: a key role for reactive oxygen species in ischemic brain injury. J. Pharmacol. Exp. Ther. (1998) 284:215-221.
133. SHIMIZU K, RAJAPAKSE N, HORIGUCHI T, PAYNE RM, BUSIJA DW: Protective effect of a new non-peptidyl mimetic of SOD, M40401, against focal cerebral ischemia in the rat. Brain Res. (2003) 963:8-14.
134. MANEV H, UZ T, KHARLAMOV A, JOO JY: Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats. FASEB J. (1996) 10:1546-1551.
135. KILIC E, OZDEMIR YG, BOLAY H, KELESTIMUR H, DALKARA T: Pinealectomy aggravates and melatonin administration attenuates brain damage in focal ischemia. J. Cereb. Blood. Flow Metab. (1999) 19:511-516.
136. WAKATSUKI A, OKATANI Y, IZUMIYA C, IKENOUE N: Melatonin protects against ischemia and reperfusion-induced oxidative lipid and DNA damage in fetal rat brain. J. Pineal Res. (1999) 26:147-152.
137. GUERRERO JM, REITER RJ, ORTIZ GG, PABLOS MI, SEWERYNEK E, CHUANG JI: Melatonin prevents increases in neural nitric oxide and cyclic GMP production after transient brain ischemia and reperfusion in the Mongolian gerbil (Meriones unguiculatus). J. Pineal Res. (1997) 23:24-31.
138. CHO S, JOH TH, BAIK HH, DIBINIS C, VOLPE BT: Melatonin administration protects CA1 hippocampal neurons after transient forebrain ischemia in rats. Brain Res. (1997) 755:335-338.
139. LI XJ, ZHANG LM, GU J, ZHANG AZ, SUN FY: [Melatonin decreases production of hydroxyl radical during cerebral ischemia-reperfusion.] Zhongguo Yao Li Xue Bao (1997) 18:394-396. Chinese.
140. LETECHIPIA-VALLEJO G, GONZALEZ-BURGOS I, CERVANTES M: Neuroprotective effect of melatonin on brain damage induced by acute global cerebral ischemia in cats. Arch. Med. Res. (2001) 32:186-192.
141. CUZZOCREA S, COSTANTINO G, GITTO E et al.: Protective effects of melatonin in ischemic brain injury. J. Pineal Res. (2000) 29:217-227.
142. BORLONGAN CV, YAMAMOTO M, TAKEI N et al.: Glial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia. FASEB J. (2000) 14:1307-1317.
143. LING X, ZHANG LM, LU SD, LI XJ, SUN FY: [Protective effect of melatonin on injuried cerebral neurons is associated with bcl-2 protein over-expression]. Zhongguo Yao Li Xue Bao (1999) 20:409-414. Chinese.
144. KONDOH T, UNEYAMA H, NISHINO H, TORII K: Melatonin reduces cerebral edema formation caused by transient forebrain ischemia in rats. Life Sci. (2002) 72:583-590.
145. EL-ABHAR HS, SHAALAN M, BARAKAT M, EL-DENSHARY ES: Effect of melatonin and nifedipine on some antioxidant enzymes and different energy fuels in the blood and brain of global ischemic rats. J. Pineal Res. (2002) 33:87-94.
146. SUN FY, LIN X, MAO LZ et al.: Neuroprotection by melatonin against ischemic neuronal injury associated with modulation of DNA damage and repair in the rat following a transient cerebral ischemia. J. Pineal Res. (2002) 33:48-56.
147. PEI Z, PANG SF, CHEUNG RT: Pretreatment with melatonin reduces volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. J. Pineal Res. (2002) 32:168-172.
148. PEI Z, HO HT, CHEUNG RT: Pre-treatment with melatonin reduces volume of cerebral infarction in a permanent middle cerebral artery occlusion stroke model in the rat. Neurosci. Lett. (2002) 18:141-144.
149. PEI Z, PANG SF, CHEUNG RT: Administration of melatonin after onset of ischemia reduces the volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. Stroke (2003) 34:770-775.
150. FIORINA P, LATTUADA G, PONARI O, SILVESTRINI C, DALLAGLIO P: Impaired nocturnal melatonin excretion and changes of immunological status in ischaemic stroke patients. Lancet (1996) 347:692-693.
151. PANG SF, LI Y, JIANG DH, CHANG B, XIE BL: Acute cerebral hemorrhage changes the nocturnal surge of plasma melatonin in humans. J. Pineal Res. (1990) 9:193-208.
152. FIORINA P, LATTUADA G, SILVESTRINI C, PONARI O, DALL'AGLIO P: Disruption of nocturnal melatonin rhythm and immunological involvement in ischaemic stroke patients. Scand. J. Immunol. (1999) 50:228-231.
153. BELOOSESKY Y, GRINBLAT J, LAUDON M, GROSMAN B, STREIFLER JY, ZISAPEL N: Melatonin rhythms in stroke patients. Neurosci. Lett. (2002) 319:103-106.
154. EBLY EM, PARHAD IM, HOGAN DB, FUNG TS: Prevalence and types of dementia in the very old: results from the Canadian Study of Health and Aging. Neurology. (1994) 44:1593-1600.
155. SYKES CM, MARKS DF, MCKINLEY JM: Alzheimer's disease and associated disorders: project funding opportunities within the European community. Alzheimer Dis. Assoc. Disord. (2001) 15:102-105.
156. BROOKMEYER R, GRAY S, KAWAS C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health. (1998) 88:1337-1342.
157. NUSSBAUM RL, ELLIS CE: Alzheimer's disease and Parkinson's disease. N. Engl. J. Med. (2003) 348:1356-1364.
158. BORCHELT DR, THINAKARAN G, ECKMAN CB et al.: Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron (1996) 17:1005-1013.
159. STRITTMATTER WJ, ROSES AD. Apolipoprotein E and Alzheimer's disease. Ann. Rev. Neurosci. (1996) 19:53-77.
160. NUNOMURA A, PERRY G, ALIEV G: et al.: Oxidative damage is the earliest event in Alzheimer's disease. J. Neuropathol. Exp. Neurol. (2001) 60:759-767.
161. GIBSON GE, HUANG HM: Oxidative processes in the brain and non-neuronal tissues as biomarkers of Alzheimer's disease. Front Biosci. (2002) 7:1007-1015.
162. TUPPO EE, FORMAN LJ: Free radical oxidative damage and Alzheimer's disease. J. Am. Osteopath. Assoc. (2001) 101(12Suppl.Pt1):S11-15.
163. MARIDONNEAU-PARINI I, TRINGALE SM, TAUBER AI: Identification of distinct activation pathways of the human neutrophil NADPH-oxidase. J. Immunol. (1986) 137:2925-2929.
164. BUTTERFIELD DA. Amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic. Res. (2002) 36:1307-1313.
165. MCLELLAN ME, KAJDASZ ST, HYMAN BT, BACSKAI BJ: In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J. Neurosci. (2003) 23:2212-2217.
166. RUTTEN BP, STEINBUSCH HW, KORR H, SCHMITZ C: Antioxidants and Alzheimer's disease: from bench to bedside (and back again). Curr. Opin. Clin. Nutr. Metab. Care (2002) 5:645-651.
167. BUTTERFIELD DA, KOPPAL T, SUBRAMANIAM R, YATIN S: Vitamin E as an antioxidant/free radical scavenger against amyloid β-peptide-induced oxidative stress in neocortical synaptosomal membranes and hippocampal neurons in culture: insights into Alzheimer's disease. Rev. Neurosci. (1999) 10:141-149.
168. YATIN SM, VARADARAJAN S, BUTTERFIELD DA: Vitamin E prevents Alzheimer's amyloid β-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production. J. Alzheimers Dis. (2000) 2:123-131.
169. MUNOZ FJ, OPAZO, C, GIL-GOMEZ G et al.: Vitamin E but not 17β-estradiol protects against vascular toxicity induced by β-amyloid wild type and the Dutch amyloid variant. J. Neurosci. (2002) 22:3081-3089.
170. PRATICO D, URYU K, SUNG S, TANG S, TROJANOWSKI JQ, LEE VM: Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB J. (2002) 16:1138-1140.
171. SANO M, ERNESTO C, THOMAS RG et al.: A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease Cooperative Study. N. Engl. J. Med. (1997) 336:1216-1222.
172. THOMAS A, IACONO D, BONANNI L, D'ANDREAMATTEO G, ONOFRJ M: Donepezil, rivastigmine, and vitamin E in Alzheimer's disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months. Clin. Neuropharmarol. (2001) 24:31-42.
173. MORRIS MC, EVANS DA, BIENIAS JL et al.: Dietary intake of antioxidant nutrients and the risk of incident Alzheimer's disease in a biracial community study. JAMA. (2002) 287:3230-3237.
174. ENGELHART MJ, GEERLINGS MI, RUITENBERG et al.: Dietary intake of antioxidants and risk of Alzheimer's disease. JAMA. (2002) 287:3223-3229.
175. VARNER AE: Antioxidants and risk of Alzheimer's disease. JAMA. (2002) 288:2265-2266.
176. LUCHSINGER JA, TANG MX, SHEA S, MAYEUX R. Antioxidant vitamin intake and risk of Alzheimer's disease. Arch. Neurol. (2003) 60:203-208.
177. PARASKEVAS GP, KAPAKI E, LIBITAKI G, ZOURNAS C, SEGDITSA I, PAPAGEORGIOU C: Ascorbate in healthy subjects, amyotrophic lateral sclerosis and Alzheimer's disease. Acta Neurol. Scand. (1997) 96:88-90.
178. RIVIERE S, BIRLOUEZ-ARAGON I, NOURHASHEMI F, VELLAS B: Low plasma vitamin C in Alzheimer patients despite an adequate diet. Int. J. Geriatr. Psychiatry. (1998) 13:749-754.
179. PREHN JH, BINDOKAS VP, JORDAN J et al.: Protective effect of transforming growth factor-β 1 on β-amyloid neurotoxicity in rat hippocampal neurons. Mol. Pharmacol. (1996) 49:319-328.
180. MEDINA S, MARTINEZ M, HERNANZ A: Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor α, dopamine and β-amyloid peptide 1-42. Free Radic. Res. (2002) 36:1179-1184.
181. PERRY TL, YONG VW, BERGERON C, HANSEN S, JONES K: Amino acids, glutathione, and glutathione transferase activity in the brains of patients with Alzheimer's disease. Ann. Neurol. (1987) 21:331-336.
182. KONINGS CH, KUIPER MA, TEERLINK T, MULDER C, SCHELTENS P, WOLTERS EC: Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy. J. Neurol. Sci. (1999) 168:112-115.
183. GU M, OWEN AD, TOFFA SE et al.: Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J. Neurol. Sci.
184. CECCHI C, LATORRACA S, SORBI S, IANTOMASI T, FAVILLI F, VINCENZINI MT et al.: Gluthatione level is altered in lymphoblasts from patients with familial Alzheimer's disease. Neurosci. Lett. (1999) 275:152-154.
185. LOVELL MA, EHMANN WD, BUTLER SM, MARKESBERY WR: Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology (1995) 45:1594-1601.
186. MARCUS DL, THOMAS C, RODRIGUEZ C et al.: Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp. Neurol. (1998) 150:40-44.
187. PEREIRA C, SANTOS MS, OLIVEIRA C.: Involvement of oxidative stress on the impairment of energy metabolism induced by A β peptides on PC12 cells: protection by antioxidants. Neurobiol. Dis. (1999) 6:209-219.
188. OLIVIERI G, BAYSANG G, MEIER F et al.: N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on β-amyloid secretion and tau phosphorylation. J. Neurochem. (2001) 76:224-233.
189. TOHGI H, ABE T, TAKAHASHI S, KIMURA M, TAKAHASHI J, KIKUCHI T. Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia. Neurosci. Lett. (1992) 141:9-12.
190. LIU RY, ZHOU JN, VAN HEERIKHUIZE J, HOFMAN MA, SWAAB DF: Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J. Clin. Endocrinol. Metab. (1999) 84:323-327.
191. REBECK GW, REITER JS, STRICKLAND DK, HYMAN BT: Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron (1993) 11:575-580.
192. MISHIMA K, TOZAWA T, SATOH K, MATSUMOTO Y, HISHIKAWA Y, OKAWA M: Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol. Psychiatry (1999) 45:417-421.
193. SAVASKAN E, OLIVIERI G, MEIER F et al.: Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J. Pineal Res. (2002) 32:59-62.
194. PAPPOLLA MA, SOS M, OMAR RA et al.: Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J. Neurosci. (1997) 17:1683-1690.
195. PAPPOLLA MA, CHYAN YJ, BOZNER P et al.: Dual anti-amyloiddogenic and antioxidant properties of melatonin. A new therapy for Alzheimer's disease. In: Research Advance in Alzheimer's disease. Iqbal K, Mortimer J, Winblad B, Wisniewski HM (Eds) Wiley and Sons, New York, USA (1999):661-669.
196. PAPPOLLA M, BOZNER P, SOTO C et al.: Inhibition of Alzheimer β-fibrillogenesis by melatonin. J. Biol. Chem. (1998) 273:7185-7188.
197. SHEN YX, XU SY, WEI W, WANG XL, WANG H, SUN X: Melatonin blocks rat hippocampal neuronal apoptosis induced by amyloid β-peptide 25-35. J. Pineal Res. (2002) 32:163-167.
198. SHEN YX, WEI W, XU SY: Protective effects of melatonin on cortico-hippocampal neurotoxicity induced by amyloid β-peptide 25-35. Acta Pharmacol. Sin. (2002) 23:71-76.
199. 4 on the Alzheimer amyloid Aβ peptide. Biochemistry (2001) 40:14995-15001.
200. OLIVIERI G, HESS C, SAVASKAN E et al.: Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased β-amyloid secretion. J. Pineal Res. (2001) 31:320-325.
201. BOZNER P, GRISHKO V, LEDOUX SP, WILSON GL, CHYAN YC, PAPPOLLA MA. The amyloid β protein induces oxidative damage of mitochondrial DNA. J. Neuropathol. Exp. Neurol. (1997) 56:1356-1362.
202. SHEN YX, XU SY, WEI W et al.: The protective effects of melatonin from oxidative damage induced by amyloid β-peptide 25-35 in middle-aged rats. J. Pineal Res. (2002) 32:85-89.
203. MATSUBARA E, BRYANT-THOMAS T, PACHECO QUINTO J et al.: Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J. Neurochem. (2003) 85:1101-1108.
204. BRUSCO LI, MARQUES M, CARDINALI DP: Monozygotic twins with Alzheimer's disease treated with melatonin: case report. J. Pineal Res. (1998) 25:260-263.
205. MAURIZI CP. Alzheimer's disease: role for mitochondrial damage, the hydroxyl radical, and cerebrospinal fluid deficiency of melatonin. Med. Hypotheses (2001) 57:156-160.
206. BRUSCO LI, MARQUES M, CARDINALI DP: Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrionol. Lett. (1998) 19:111-115.
207. COHEN-MANSFIELD J, GARFINKEL D, LIPSON S: Melatonin for treatment of sundowning in elderly persons with dementia - a preliminary study. Arch. Gerontr. Geriatr. (2000) 31:65-76.
208. ASAYAMA K, YAMADERA H, ITO T, SUZUKI H, KUDO Y, ENDO S: Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in alzheimer type dementia. J. Nippon Med. Sch. (2003) 70:334-341.
209. BRUCE AJ, MALFROY B, BAUDRY M: β-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger. Proc. Natl. Acad. Sci. USA (1996) 93:2312-2316.
210. TANNER CM, GOLDMAN SM: Epidemiology of Parkinson's disease. Neurol. Clin. (1996) 14:317-335.
211. LYRAS L, PERRY RH, PERRY EK et al.: Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies. J. Neurochem. (1998) 71:302-312.
212. JENNER P: Oxidative stress in Parkinson's disease. Ann. Neurol. (2003) 53(Suppl.3):S26-36.
213. GRAHAM DG: Oxidative pathways for catecholamines in genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. (1978) 14:633-643.
214. OLANOW CW: Oxidation reactions in Parkinson's disease. Neurology (1990) 40(Suppl.3):32-37.
215. PEDROSA R, SOARES-DA-SILVA P: Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine(L-DOPA) and dopamine. Br. J. Pharmacol. (2002) 137:1305-1313.
216. ADAMS JD Jr, CHANG ML, KLAIDMAN L, ADAMS JD JR, CHANG ML, KLAIDMAN L: Parkinson's disease-redox mechanisms. Curr. Med. Chem. (2001) 8:809-814.
217. CUTILLAS B, AMBROSIO S, UNZETA M: Neuroprotective effect of the monoamine oxidase inhibitor PF-9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion. Neurosci. Lett. (2002) 329:165-168.
218. GOOD PF, OLANOW CW, PERL DP: Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. (1992) 593:343-346.
219. BLUM D, TORCH S, LAMBENG N et al.: Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. (2001) 65:135-172.
220. MARSDEN CD, JENNER PG: The significance of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Ciba Found Symp. (1987) 126:239-256.
221. GERLACH M, RIEDERER P: Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural. Transm. (1996) 103:987-1041.
222. GERLACH M, RIEDERER P, PRZUNTEK H, YOUDIM MB: MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol. (1991) 208:273-286.
223. + opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim. Biophys. Acta (1999) 1453:49-62.
224. GOMEZ C, REIRIZ J, PIQUE M, GIL J, FERRER I, AMBROSIO S: Low concentrations of 1-methyl-4-phenylpyridinium ion induce caspase-mediated apoptosis in human SH-SY5Y neuroblastoma cells. J. Neurosci. Res. (2001) 63:421-428.
225. STEPHANS SE, MILLER GW, LEVEY AI, GREENAMYRE JT: Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells. Neurotoxicology (2002) 23:569-580.
226. TORNERO D, CENA V, GONZALEZ-GARCIA C, JORDAN J: The role of the mitochondrial permeability transition pore in neurodegenerative processes. Rev. Neurol. (2002) 35:354-61.
227. EBADI M, GOVITRAPONG P, SHARMA S et al.: Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of Parkinson's disease. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of Parkinson's disease. Biol. Signals Recept. (2001) 10:224-253.
228. TOHGI H, ABE T, SAHEKI M, HAMATO F, SASAKI K, TAKAHASHI S: Reduced and oxidized forms of glutathione and α-tocopherol in the cerebrospinal fluid of parkinsonian patients: comparison between before and after L-dopa treatment. Neurosci. Lett. (1995) 184:21-24.
229. MOLINA JA, DE BUSTOS F, JIMENEZ-JIMENEZ FJ et al.: Cerebrospinal fluid levels of α-tocopherol (vitamin E) in Parkinson's disease. J. Neural. Transm. (1997) 104:1287-1293.
230. STORCH A, KAFTAN A, BURKHARDT K, SCHWARZ J: 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism. J. Neural. Transm. (2000) 107:281-293.
231. + neurotoxicity against rat dopaminergic neurons in culture. Neurosci. Lett. (1995) 193:53-56.
232. SANCHEZ-RAMOS JR, MICHEL P, WEINER WJ, HEFTI F: Selective destruction of cultured dopaminergic neurons from fetal rat mesencephalon by 1-methyl-4-phenylpyridinium: cytochemical and morphological evidence. J Neurochem. (1988) 50:1934-1944.
233. +) in cerebellar granule cells. J. Neurochem. (2003) 84:305-315.
234. CADET JL, KATZ M, JACKSON-LEWIS V, FAHN S: Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res. (1989) 476:10-15.
235. HEIM C, KOLASIEWICZ W, KURZ T, SONTAG KH: Behavioral alterations after unilateral 6-hydroxydopamine lesions of the striatum. Effect of α-tocopherol. Pol. J. Pharmacol. (2001) 53:435-448.
236. ROGHANI M, BEHZADI G: Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. Brain Res. (2001) 892:211-217.
237. PERRY TL, YONG VW, CLAVIER RM et al.: Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett. (1985) 60:109-114.
238. PERRY TL, YONG VW, HANSEN S et al.: α-tocopherol and β-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurol. Sci. (1987) 81:321-331.
239. SELLEY ML: (E)-4-Hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic. Biol. Med. (1998) 2:169-174.
240. +. Brain Res. (2002) 941:72-81.
241. GONG L, DAIGNEAULT EA, ACUFF RV, KOSTRZEWA RM: Vitamin E supplements fail to protect mice from acute MPTP neurotoxicity. Neuroreport (1991) 2:544-546.
242. MIHATSCH W, RUSS H, GERLACH M, RIEDERER P, PRZUNTEK H: Treatment with antioxidants does not prevent loss of dopamine in the striatum of MPTP-treated common marmosets: preliminary observations. J. Neural Transm. Park. Dis. Dement. Sect. (1991) 3:73-78.
243. PARKINSON STUDY GROUP: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. (1993) 328: 176-183.
244. FAHN S: A pilot trial of high-dose α-tocopherol and ascorbate in early Parkinson's disease. Ann. Neurol. (1992) 32(Suppl.):S128-132.
245. FARISS MW, ZHANG JG: Vitamin E therapy in Parkinson's disease. Toxicology (2003) 189:129-146.
246. GOLBE LI, FARRELL TM, DAVIS PH: Case-control study of early life dietary factors in Parkinson's disease. Arch. Neurol. (1988) 45:1350-1353.
247. DE RIJK MC, BRETELER MM, DEN BREEIJEN JH et al.: Dietary antioxidants and Parkinson's disease. The Rotterdam Study. Arch. Neurol. (1997) 54:762-765.
248. ZHANG SM, HERNAN MA, CHEN H, SPIEGELMAN D, WILLETT WC, ASCHERIO A: Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurologv (2002) 59:1161-1169.
249. FERNANDEZ-CALLE P, JIMENEZ-JIMENEZ FJ, MOLINA JA et al.: Serum levels of ascorbic acid (vitamin C) in patients with Parkinson's disease. J. Neurol. Sci. (1993) 118:25-28.
250. YAPA SC: Detection of subclinical ascorbate deficiency in early Parkinson's disease. Detection of subclinical ascorbate deficiency in early Parkinson's disease. Public Health. (1992) 106:393-395.
251. KING D, PLAYFER JR, ROBERTS NB: Concentrations of vitamins A, C and E in elderly patients with Parkinson's disease. Postgrad Med. J. (1992) 68:634-637.
252. SOTO-OTERO R, MENDEZ-ALVAREZ E, HERMIDA-AMEIJEIRAS A, MUNOZ-PATINO AM, LABANDEIRA-GARCIA JL: Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J. Neurochem. (2000) 74:1605-1612.
253. CHOI HY, SONG JH, PARK DK, ROSS GM: The effects of ascorbic acid on dopamine-induced death of PC12 cells are dependent on exposure kinetics. Neurosci. Lett. (2000) 296:81-84.
254. SAWADA H, SHIMOHAMA S, KAWAMURA T et al.: Mechanism of resistance to NO-induced neurotoxicity in cultured rat dopaminergic neurons. J. Neurosci. Res. (1996) 46:509-518.
255. SCHEIDER WL, HERSHEY LA, VENA JE, HOLMLUND T, MARSHALL JR, FREUDENHEIM: Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease. Mov. Disord. (1997) 12:190-196.
256. KONINGS CH, KUIPER MA, TEERLINK T, MULDER C, SCHELTENS P, WOLTERS EC: Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy. J. Neurol. Sci. (1999) 168:112-115.
257. SIAN J, DEXTER DT, LEES AJ, DANIEL S, AGID Y, JAVOY-AGID et al.: Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. (1994) 36:333-334.
258. OWEN AD, SCHAPIRA AH, JENNER P, MARSDEN CD: Oxidative stress and Parkinson's disease. Ann. NY Acad. Sci. (1996) 786:217-223.
259. SIAN J, DEXTER DT, LEES AJ, DANIEL S, JENNER P, MARSDEN CD: Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurol. (1994) 36:356-361.
260. JENNER P: Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. (1998) 13(Suppl.1):24-34.
261. TARIQ M, KHAN HA, AL MOUTAERY K, AL DEEB S: Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents. Brain Res. Bull. (2001) 54:77-82.
262. +) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rat. Neurosci. Lett. (1993) 161:121-123.
263. MCNAUGHT KS, JENNER P: Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. J. Neurochem. (1999) 73:2469-2476.
264. OFFEN D, ZIV I, STERNIN H, MELAMED E, HOCHMAN A: Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp. Neurol. (1996) 141:32-39.
265. + toxicity in nigral dopaminergic neurones. Neuroreport (1996) 7:921-923.
266. GARCIA JC, REMIRES D, LEIVA A, GONZALEZ R: Depletion of brain glutathione potentiates the effect of 6-hydroxydopamine in a rat model of Parkinson's disease. J. Mol. Neurosci. (2000) 14:147-153.
267. PILEBLAD E, MAGNUSSON T, FORNSTEDT B: Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxydopamine in rat striatum. J. Neurochem. (1989) 52:978-980.
268. DESOLE MS, ESPOSITO G, ENRICO P et al.: Effects of ageing on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxic effects on striatum and brainstem in the rat. Neurosci. Lett. (1993) 159:143-146.
269. PERRY TL, YONG VW, CLAVIER RM et al.: Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett. (1985) 60:109-114.
270. MOUSSAOUI S, OBINU MC, DANIEL N, REIRAUD M, BLANCHARD V, IMPERATO A: The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp. Neurol. (2000) 166:235-245.
271. FERTL E, AUFF E, DOPPELBAUER A, WALDHAUSER F: Circadian secretion pattern of melatonin in Parkinson's disease. J. Neural. Transm. Park. Dis. Dement. Sect. (1991) 3:41-47.
272. FERTL E, AUFF E, DOPPELBAUER A, WALDHAUSER F: Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of 1-dopa. J. Neural. Transm. Park. Dis. Dement. Sect. (1993) 5:227-234.
273. CATALA MD, CANETE-NICOLAS C, IRADI A, TARAZONA PJ, TORMOS JM, PASCUAL-LEONE A: Melatonin levels in Parkinson's disease: drug therapy versus electrical stimulation of the internal globus pallidus. Exp. Gerontol. (1997) 32:553-558.
274. GHAEMI M, RUDOLF J, HILKER R, HERHOLZ K, HEISS W-D: Increased pineal F-dopa uptake is related to severity of Parkinson's disease - A PET study. J. Pineal Res. (2001) 30:213-219.
275. MAYO JC, SAINZ RM, URIA H, ANTOLIN I, ESTEBAN MM, RODRIGUEZ C: Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease. J. Pineal Res. (1998) 24:179-192.
276. MAYO JC, SAINZ RM, URIA H, ANTOLIN I, ESTEBAN MM, RODRIGUEZ: Inhibition of cell proliferation: a mechanism likely to mediate the prevention of neuronal cell death by melatonin. J. Pineal Res. (1998) 25:12-18.
277. MAYO JC, SAINZ RM, ANTOLIN I, RODRIGUEZ C: Ultrastructural confirmation of neuronal protection by melatonin against the neurotoxin 6-hydroxydopamine cell damage. Brain Res. (1999) 818:221-227.
278. PARK JW, YOUN YC, KWON OS, JANG YY, HAN ES, LEE CS: Protective effect of serotonin on 6-hydroxydopamine-and dopamine-induced oxidative damage of brain mitochondria and synaptosomes and PC12 cells. Neurochem. Int. (2002) 40:223-233.
279. IACOVITTI L, STULL ND, JOHNSTON K: Melatonin rescues dopamine neurons from cell death in tissue culture models of oxidative stress. Brain Res. (1997) 768:317-326.
280. STULL ND, POLAN DP, IACOVITTI L: Antioxidant compounds protect dopamine neurons from death due to oxidative stress in vitro. Brain Res. (2002) 931:181-185.
281. TENN CC, NILES LP: Central-type benzodiazepine receptors mediate the antidopaminergic effect of clonazepam and melatonin in 6-hydroxydopamine lesioned rats: involvement of a GABAergic mechanism. J. Pharmacol. Exp. Ther. (1995) 274:84-89.
282. KIM YS, JOO WS, JIN BK, CHO YH, BAIK HH, PARK CW: Melatonin protects 6-OHDA-induced neuronal death of nigrostriatal dopaminergic system. Neuroreport (1998) 9:2387-2390.
283. JOO WS, JIN BK, PARK CW, MAENG SH, KIM YS: Melatonin increases striatal dopaminergic function in 6-OHDA-lesioned rats. Neuroreport (1998) 9:4123-4126.
284. DABBENI-SALA F, DI SANTO S, FRANCESCHINI D, SKAPER SD, GIUSTI P: Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J. (2001) 15:164-170.
285. AGUIAR LM, VASCONCELOS SM, SOUSA FC, VIANA GS: Melatonin reverses neurochemical alterations induced by 6-OHDA in rat striatum. Life Sci. (2002) 70:1041-1051.
286. ACUNA-CASTROVIEJO D, COTO-MONTES A, GAIA MONTI M, ORTIZ GG, REITER RJ: Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci. (1997) 60:PL23-29.
287. TANG YP, MA YL, CHAO CC, CHEN KY, LEE EH: Enhanced glial cell line-derived neurotrophic factor mRNA expression upon (-)-deprenyl and melatonin treatments. J. Neurosci. Res. (1998) 53:593-604.
288. ORTIZ GG, CRESPO-LOPEZ ME, MORAN-MOGUEL C, GARCIA JJ, REITER RJ, ACUNA-CASTROVIEJO D: Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo. Neuroendocrinol. Lett. (2001) 22:101-108.
289. LI XJ, GU J, LU SD, SUN FY: Melatonin attenuates MPTP-induced dopaminergic neuronal injury associated with scavenging hydroxyl radical. J. Pineal Res. (2002) 32:47-52.
290. ANTOLIN I, MAYO JC, SAINZ RM et al.: Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res. (2002) 943:163-173.
291. KHALDY H, ESCAMES G, LEON J, BIKJDAOUENE L, ACUNA-CASTROVIEJO D: Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion. Neurobiol. Aging (2003) 24:491-500.
292. ITZHAK Y, MARTIN JL, BLACK MD, ALI SF: Effect of melatonin on methamphetamine- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity and methamphetamine-induced behavioral sensitization. Neuropharmacologv. (1998) 37:781-791.
293. VAN DER SCHYF CJ, CASTAGNOLI K, PALMER S, HAZELWOOD L, CASTAGNOLI N JR: Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum. Neurotox. Res. (2000) 1:261-269.
294. MORGAN WW, NELSON JF: Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway. Brain Res. (2001) 921:115-121.
295. YAN MT. Melatonin has antioxidant effects in the brain. J. Pineal Res. (2002) 33:125-126.
296. VATASSERY GT, NELSON MJ, MALETTA GJ, KUSKOWSKI MA: Vitamin E (tocopherols) in human cerebrospinal fluid. Am. J. Clin. Nutr. (1991) 53:95-99.
297. VATASSERY GT, ANGERHOFER CK, PETERSON FJ: Vitamin E concentrations in the brains and some selected peripheral tissues of selenium-deficient and vitamin E-deficient mice. J. Neurochem. (1984) 42:554-558.
298. MARTIN A, PRIOR R, SHUKITT-HALE B, CAO G, JOSEPH JA: Effect of fruits, vegetables, or vitamin E-rich diet on vitamins E and C distribution in peripheral and brain tissues: implications for brain function. J. Gerontol. A Biol. Sci. Med. Sci. (2000) 55:B144-B151
299. ACUNA-CASTROVIEJO D, ESCAMES G, CARAZO A, LEON J, KHALDY H, REITER RJ: Melatonin, mitochondrial homeostasis and mitochondrial-related diseases. Curr. Top. Med. Chem. (2002) 2:133-151.
300. MAHAL HS, SHARMA HS, MUKHERJEE T: Antioxidant properties of melatonin: a pulse radiolysis study. Free Radic. Biol. Med. (1999) 26:557-565
301. GITTO E, TAN DX, REITER RJ et al.: Individual and synergistic antioxidative actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in rat liver homogenates. J. Pharm. Pharmacol. (2001) 53:1393-1401.
302. TAN DX, HARDELAND R, MANCHESTER LC et al.: Mechanistic and comparative studies of melatonin and classic antioxidants in terms of their interactions with the ABTS cation radical. J. Pineal Res. (2003) 34:249-259.
303. KONTUSH A, MANN U, ARLT S et al.: Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer's disease. Free Radic. Biol. Med. (2001) 31:345-354.
304. CUZZOCREA S, REITER RJ: Pharmacological actions of melatonin in acute and chronic inflammation. Curr. Top. Med. Chem. (2002) 2:153-165.
305. OLANOW CW: Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action. J. Neural. Transm. Suppl. (1996) 48:75-84.
306. MALLY J, KOVACS AB, STONE TW: Delayed development of symptomatic improvement by (-)-deprenyl in Parkinson's disease. J. Neurol. Sci. (1995) 134:143-145.